Inventor · disambiguated record
Mark Ian Kemp
Also filed as: KEMP MARK I · KEMP MARK IAN · KEMP Mark
43 granted patents·12 pending applications·231 citations·filing 1999–2022
97Inventor score
Top patents by PatentIndex Score
55 records- 0194US9926307B2CompoundsMISSION THERAPEUTICS LTD·Filed 2015·Granted Mar 27, 2018·14 cites·16 claims
- 0293US10343992B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2016·Granted Jul 9, 2019·7 cites·2 claims
- 0392US10689345B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jun 23, 2020·4 cites·14 claims
- 0490US6770645B2Pharmaceutically active compoundsPFIZER·Filed 2002·Granted Aug 3, 2004·51 cites·13 claims
- 0589US10392380B2CompoundsMISSION THERAPEUTICS LTD·Filed 2018·Granted Aug 27, 2019·6 cites·17 claims
- 0687US11130748B2CompoundsMISSION THERAPEUTICS LTD·Filed 2016·Granted Sep 28, 2021·3 cites·12 claims
- 0787US10774078B2CompoundsMISSION THERAPEUTICS LTD·Filed 2019·Granted Sep 15, 2020·2 cites·10 claims
- 0887US6784185B2Pharmaceutically active compoundsPFIZER·Filed 2002·Granted Aug 31, 2004·35 cites·7 claims
- 0986US11472798B2CompoundsMISSION THERAPEUTICS LTD·Filed 2020·Granted Oct 18, 2022·1 cites·11 claims
- 1085US10640498B2CompoundsMISSION THERAPEUTICS LTD·Filed 2017·Granted May 5, 2020·6 cites·17 claims
- 1183US11390584B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Granted Jul 19, 2022·1 cites·14 claims
- 1281US11993595B2CompoundsMISSION THERAPEUTICS LTD·Filed 2022·Granted May 28, 2024·0 cites·10 claims
- 1380US6794387B2Pharmaceutically active compoundsPFIZER·Filed 2002·Granted Sep 21, 2004·11 cites·14 claims
- 1480US6372736B1Heterocyclic compounds as inhibitors of rotamase enzymesPFIZER·Filed 1999·Granted Apr 16, 2002·43 cites·31 claims
- 1579US7572797B2Amino substituted pyrazine derivatives for the treatment of painPFIZER·Filed 2006·Granted Aug 11, 2009·6 cites·10 claims
- 1678US9079878B2(4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulatorsPFIZER LTD·Filed 2012·Granted Jul 14, 2015·5 cites·11 claims
- 1778US8134007B2Pyridine derivativesBAGAL SHARANJEET KAUR·Filed 2008·Granted Mar 13, 2012·8 cites·23 claims
- 1878US2022251041A11-cyano-pyrrolidine compounds as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1975US7456164B23- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligandsPFIZER·Filed 2005·Granted Nov 25, 2008·3 cites·23 claims
- 2074US6686357B1FKBP inhibitorsPFIZER·Filed 2000·Granted Feb 3, 2004·5 cites·25 claims
- 2173US10669234B2Cyanopyrrolidines as dub inhibitors for the treatment of cancerMISSION THERAPEUTICS LTD·Filed 2016·Granted Jun 2, 2020·1 cites·15 claims
- 2272US10683269B22-cyanoisoindoline derivatives for treating cancerMISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 16, 2020·1 cites·15 claims
- 2370US11066365B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jul 20, 2021·0 cites·14 claims
- 2470US11053198B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jul 6, 2021·0 cites·4 claims
- 2570US2022106315A1Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitorsMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2668US11958833B2CompoundsMISSION THERAPEUTICS LTD·Filed 2021·Granted Apr 16, 2024·0 cites·14 claims
- 2768US11945797B21-cyano-pyrrolidine derivatives as dub inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Granted Apr 2, 2024·0 cites·15 claims
- 2868US6509464B1FKBP inhibitorsPFIZER·Filed 2000·Granted Jan 21, 2003·3 cites·1 claims
- 2968US6495549B1FKBP inhibitorsPFIZER·Filed 2000·Granted Dec 17, 2002·3 cites·18 claims
- 3066US11236092B2Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Granted Feb 1, 2022·0 cites·10 claims
- 3166US6562964B1Heterocyclic compounds as inhibitors of rotamase enzymesPFIZER·Filed 2002·Granted May 13, 2003·2 cites·4 claims
- 3262US2025034122A1Substituted n-cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3360US11319287B2Cyanopyrrolidines as dub inhibitors for the treatment of cancerMISSION THERAPEUTICS LTD·Filed 2020·Granted May 3, 2022·0 cites·15 claims
- 3454US6166011AFKBP inhibitorsPFIZER·Filed 1999·Granted Dec 26, 2000·10 cites·29 claims
- 3554US2023219939A1N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunctionMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 3654US2023312580A11-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosisMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 3754US2023303547A1N-cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 3853US10654853B2Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitorsMISSION THERAPEUTICS LTD·Filed 2017·Granted May 19, 2020·0 cites·10 claims
- 3953US2023119013A1N-cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 4050US2022315572A1Substituted cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 4149US2004058905A1FKBP inhibitorsPFIZER·Filed 2003·Application pending·0 cites
- 4249US2010227872A1Pyrazine derivativesKEMP MARK IAN·Filed 2008·Application pending·0 cites
- 4348US11352339B21-cyano-pyrrolidine derivatives as DUB inhibitorsMISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 7, 2022·0 cites·15 claims
- 4446US11414402B2Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitorsMISSION THERAPEUTICS LTD·Filed 2018·Granted Aug 16, 2022·0 cites·14 claims
- 4546US10927110B2Cyano-subtituted heterocycles with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted Feb 23, 2021·0 cites·16 claims
- 4644US11059809B2Substituted cyanopyrrolidines with activity as DUB inhibitorsMISSION THERAPEUTICS LTD·Filed 2018·Granted Jul 13, 2021·0 cites·16 claims
- 4743US11370784B2Cyano-substituted heterocycles with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 28, 2022·0 cites·14 claims
- 4842US11084821B2Cyanopyrrolidine derivatives with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted Aug 10, 2021·0 cites·19 claims
- 4941US11014912B2Cyanopyrrolidine derivatives with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted May 25, 2021·0 cites·17 claims
- 5041US2021002262A1Cyanopyrrolidines as usp30 inhibitors and fibrosis treatmentMISSION THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →